Abstract | BACKGROUND: METHODS: For this objective, a prospective cohort of n = 80 RA patients starting anti-TNF therapy was recruited. Serum determinations at baseline were performed for RF, anti-CCP, anti-CarP and anti-PAD4 antibodies using enzyme-linked immunosorbent assays (ELISA). The clinical response to anti-TNF therapy was determined at week 12 using the change in DAS28 score. Association was performed using multivariate linear regression adjusting for baseline DAS28, sex and age. RESULTS: The interaction between pairs of antibodies was tested by the addition of an interaction term. We found two highly significant antibody interactions associated with treatment response: anti-CarP with anti-PAD4 (p = 0.0062), and anti-CCP with RF (p = 0.00068). The latter antibody interaction was replicated in an independent retrospective cohort of RA patients (n = 199, p = 0.04). CONCLUSIONS: The results of this study suggest that antibody interaction effects are important factors in the response to anti-TNF therapy in RA.
|
Authors | Antonio Julià, María López-Lasanta, Francisco Blanco, Antonio Gómez, Isabel Haro, Antonio Juan Mas, Alba Erra, Ma Luz García Vivar, Jordi Monfort, Simón Sánchez-Fernández, Isidoro González, Mercedes Alperi, Raúl Castellanos-Moreira, Antonio Fernández-Nebro, César Díaz-Torné, Núria Palau, Raquel Lastra, Jordi Lladós, Raimon Sanmartí, Sara Marsal |
Journal | BMC musculoskeletal disorders
(BMC Musculoskelet Disord)
Vol. 22
Issue 1
Pg. 372
(Apr 21 2021)
ISSN: 1471-2474 [Electronic] England |
PMID | 33882889
(Publication Type: Journal Article)
|
Chemical References |
- Autoantibodies
- Peptides, Cyclic
- Tumor Necrosis Factor Inhibitors
- Rheumatoid Factor
|
Topics |
- Arthritis, Rheumatoid
(diagnosis, drug therapy)
- Autoantibodies
- Humans
- Peptides, Cyclic
- Prospective Studies
- Retrospective Studies
- Rheumatoid Factor
- Tumor Necrosis Factor Inhibitors
(therapeutic use)
|